Uncategorized Archives - Page 9 of 151

WednesdayOct 01, 2025 9:00 am

Lantern Pharma Inc.’s (NASDAQ: LTRN) AI-powered PredictBBB.ai Platform Helps Hoth Therapeutics Streamline Candidate Selection in Drug Development

Hoth Therapeutics (NASDAQ: HOTH) is using Lantern Pharma’s (NASDAQ: LTRN) PredictBBB.ai(TM) platform to accelerate development timelines, reduce risk, and improve candidate selection. This technology helps determine whether or not a candidate is able to cross the blood-brain barrier or not, which is a major holdup for many drug development companies. Leadership at both Lantern Pharma and Hoth Therapeutics are enthusiastic about the collaboration and how it can help deliver life-changing therapies for patients. Hoth Therapeutics (NASDAQ: HOTH), a biopharmaceutical company, recently announced that the company is using an AI-powered platform developed by Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotech company…

TuesdaySep 30, 2025 10:30 am

FDA Guidance Sets Lantern Pharma Inc. (NASDAQ: LTRN) On a Path Toward Realizing Its Clinical Trial Plans for Rare Pediatric Cancer Therapy

Texas-based clinical-stage biotechnology company Lantern Pharma Inc. is developing a number of clinical trials, using its proprietary drug candidates and computational biology and machine learning platform, to target conditions with unmet medical needs A recent Type C meeting with the U.S. Food and Drug Administration provided the company with guidance in working through the regulatory pathway and designing the trial for its investigational therapy LP-184/STAR-001, which will seek a means of battling pediatric brain cancers Lantern Pharma is also using drug candidates in trials to combat glioblastoma (“GBM”), triple-negative breast cancer, non-small cell lung cancer in non-smokers, non-Hodgkin’s lymphoma, and…

MondaySep 29, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Advances Psoriasis Trial with Encouraging Patient Results, Market Potential

Soligenix is positioning itself to expand its presence in dermatology with a novel therapeutic option for one of the most prevalent autoimmune skin conditions. The company’s current study aims to further assess safety and biological activity of SGX302, as well as generate additional data to guide larger studies. SGX302 has already demonstrated positive results in a phase 1/2 pilot study. Psoriasis remains a persistent challenge for millions of patients worldwide, and promising new treatments are being closely watched by the medical and investor communities alike. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases and inflammatory conditions, is advancing…

FridaySep 26, 2025 12:00 pm

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): Anticipating Tomorrow’s Imaging Standards Today

CMS proposal keeps CT radiation quality measure voluntary, highlighting ongoing debate around dose safety and image quality Izotropic’s IzoView breast CT system engineered to deliver low-dose, high-resolution 3D imaging, aligning with future regulatory and clinical priorities Company launches new FAQ page to enhance transparency for investors, clinicians, and decision-makers In medical imaging, technology often races ahead of regulation. A recent proposal from the Centers for Medicare & Medicaid Services (CMS) underscores this tension: the agency is opting not to mandate radiation dose tracking for CT scans by 2027. While the decision reflects operational challenges hospitals face in meeting such requirements,…

ThursdaySep 25, 2025 9:00 am

Researchers Find That Common Nutrient Could Supercharge the Immune Cells Fighting Cancer

A recently published study by a team at the University of Chicago suggests that a carotenoid called zeaxanthin, naturally occurring in plants like kale, spinach and orange peppers, and well known for its benefits in eye health, could also play a role in supercharging the immune system during the fight against cancer. The research, which appeared in Cell Reports Medicine, indicates that this over-the-counter supplement that is not only affordable but also easily accessible may boost the efficacy of cancer immunotherapies. The study’s senior author, Jing Chen, PhD, explains that the team was surprised when they found that the nutrient…

WednesdaySep 24, 2025 11:15 am

Soligenix Inc. (NASDAQ: SNGX) Strengthens Position in CTCL Treatment with HyBryte(TM) FLASH Results

The original FLASH study enrolled 169 patients across three treatment cycles. The ongoing FLASH 2 trial builds on findings found in the first study while addressing regulatory requirements for confirmatory evidence. For Soligenix, the FLASH studies represent more than clinical milestones. These studies are key steps in the company’s regulatory and commercial journey. Soligenix (NASDAQ: SNGX) is continuing to build momentum in its mission to advance HyBryte(TM), a first-in-class treatment for early-stage cutaneous T-cell lymphoma (“CTCL”). That progress is supported by results from its pivotal FLASH trial and its ongoing FLASH 2 confirmatory study. Together, the studies highlight not only the…

TuesdaySep 23, 2025 10:30 am

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) CEO Featured in BMW Podcast Discussing Breakthrough Breast CT Imaging

“Screening is the first line of defense,” said IZO CEO Robert Thast, who noted that company’s Breast CT technology can detect cancers as small as two millimeters. Thast summarized Izotropic’s recent advances in artificial intelligence. Company’s commercialization plans start in Europe and then expand to U.S, with focus on selling primarily to hospitals, medical facilities and imaging clinics. A new episode of the BioMedWire Podcast shines a spotlight on Izotropic (CSE: IZO) (OTCQB: IZOZF) and its innovative approach to breast cancer imaging. Featuring IZO CEO Robert Thast, the podcast (ibn.fm/JUWtD) reveals how Izotropic’s proprietary Breast CT technology could transform early…

FridaySep 19, 2025 10:30 am

Oncotelic Therapeutics Inc. (OTLC): Leadership and Innovation Drive Late-Stage Biotech Momentum

CEO Dr. Vuong Trieu recognized as inventor of multibillion-dollar oncology assets, including Abraxane(R) and Cynviloq(TM) OTLC advancing late-stage pipeline led by OT-101 in Phase 3 for pancreatic cancer and multiple other high-unmet-need indications Recent progress includes 2 years of steady clinical and regulatory advancements across oncology and rare pediatric programs The biotechnology sector is defined by its ability to pair scientific innovation with leadership that can translate discoveries into approved therapies. This is particularly critical in oncology, where late-stage candidates must navigate complex regulatory pathways and demonstrate real clinical impact in indications with limited treatment options. Companies that combine robust…

WednesdaySep 17, 2025 9:00 am

Oncotelic Therapeutics Inc. (OTLC) Champions Targeted RNA Therapy for Underserved Cancers

On the global stage, the Cancer Atlas estimates a dramatic rise in cancer cases, adding urgency to the need for therapeutic innovation Oncotelic’s mission focuses on developing first-in-class RNA therapeutics and small-molecule drugs to serve high-unmet-need cancers and rare pediatric diseases This year, the company achieved a major milestone by successfully completing a phase 1 clinical trial evaluating OT-101 combining Interleukin-2 In a landscape where cancer and underserved diseases continue to devastate millions, the demand for groundbreaking RNA-based, immunotherapeutic, and targeted treatments has never been more urgent. Oncotelic Therapeutics (OTCQB: OTLC) is answering this call with pioneering RNA candidates and strategic programs aimed at…

TuesdaySep 16, 2025 9:45 am

Clene Inc.’s (NASDAQ: CLNN) Lead Candidate CNM-Au8(R) Shows Promise in Improving Cellular Health in Parkinson’s Disease

Clene Inc. reported new preclinical data on its drug candidate CNM-Au8 for Parkinson’s disease. The therapy improved mitochondrial health, restored cellular metabolism, reduced inflammation, and normalized gene expression in dopaminergic neurons. Findings were presented at the Michael J. Fox Foundation’s H2 Therapeutics Stewardship Meeting in New York City. CNM-Au8 previously showed positive energetic and metabolic effects in a Phase 2 Parkinson’s trial, aligning with the new preclinical results. The treatment demonstrated no toxicity in neuronal models, consistent with safety data from over 1,000 patient-years in ALS and MS trials. Clene plans to design a Phase 2 clinical study for Parkinson’s…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Lantern Pharma Inc.’s (NASDAQ: LTRN) AI-powered PredictBBB.ai Platform Helps Hoth Therapeutics Streamline Candidate Selection in Drug Development

FDA Guidance Sets Lantern Pharma Inc. (NASDAQ: LTRN) On a Path Toward Realizing Its Clinical Trial Plans for Rare Pediatric Cancer Therapy

Soligenix Inc. (NASDAQ: SNGX) Advances Psoriasis Trial with Encouraging Patient Results, Market Potential

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): Anticipating Tomorrow’s Imaging Standards Today

Researchers Find That Common Nutrient Could Supercharge the Immune Cells Fighting Cancer

Soligenix Inc. (NASDAQ: SNGX) Strengthens Position in CTCL Treatment with HyBryte(TM) FLASH Results

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) CEO Featured in BMW Podcast Discussing Breakthrough Breast CT Imaging

Oncotelic Therapeutics Inc. (OTLC): Leadership and Innovation Drive Late-Stage Biotech Momentum

Oncotelic Therapeutics Inc. (OTLC) Champions Targeted RNA Therapy for Underserved Cancers

Clene Inc.’s (NASDAQ: CLNN) Lead Candidate CNM-Au8(R) Shows Promise in Improving Cellular Health in Parkinson’s Disease

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search